US 10,376,674 B2
System and method for targeted delivery of therapeutic agents to tissue
Kevin Weadock, Hillsborough, NJ (US); and Jeffrey Hammond, Bernardsville, NJ (US)
Filed by Ethicon, Inc., Somerville, NJ (US)
Filed on Sep. 15, 2014, as Appl. No. 14/485,853.
Prior Publication US 2016/0074626 A1, Mar. 17, 2016
Int. Cl. A61B 17/34 (2006.01); A61M 25/01 (2006.01); A61N 5/10 (2006.01); A61K 31/7068 (2006.01); A61K 31/513 (2006.01); A61K 31/4375 (2006.01); A61K 31/282 (2006.01); A61K 38/38 (2006.01); A61K 33/24 (2019.01); A61K 31/704 (2006.01); A61K 31/337 (2006.01); A61N 5/02 (2006.01); A61N 1/20 (2006.01); A61N 5/00 (2006.01); A61M 25/09 (2006.01); A61B 1/04 (2006.01); A61B 1/06 (2006.01); A61N 1/05 (2006.01); A61M 25/06 (2006.01); A61M 31/00 (2006.01); A61M 37/00 (2006.01); A61B 90/00 (2016.01); A61N 1/32 (2006.01); A61B 1/015 (2006.01); A61B 5/00 (2006.01); A61B 18/00 (2006.01); A61B 10/02 (2006.01); A61B 6/12 (2006.01); A61B 8/08 (2006.01); A61B 5/055 (2006.01)
CPC A61M 25/0169 (2013.01) [A61B 1/04 (2013.01); A61B 1/06 (2013.01); A61B 17/3421 (2013.01); A61B 17/3468 (2013.01); A61B 90/39 (2016.02); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4375 (2013.01); A61K 31/513 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 38/385 (2013.01); A61M 25/06 (2013.01); A61M 25/09 (2013.01); A61M 31/00 (2013.01); A61M 31/002 (2013.01); A61M 31/007 (2013.01); A61M 37/0092 (2013.01); A61N 1/05 (2013.01); A61N 1/20 (2013.01); A61N 5/00 (2013.01); A61N 5/02 (2013.01); A61N 5/1001 (2013.01); A61N 5/1027 (2013.01); A61B 1/015 (2013.01); A61B 5/055 (2013.01); A61B 5/4839 (2013.01); A61B 6/12 (2013.01); A61B 8/085 (2013.01); A61B 10/0233 (2013.01); A61B 90/361 (2016.02); A61B 2017/3445 (2013.01); A61B 2018/00005 (2013.01); A61B 2018/00273 (2013.01); A61B 2018/00601 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/00982 (2013.01); A61B 2018/00994 (2013.01); A61B 2090/3908 (2016.02); A61B 2090/3987 (2016.02); A61M 2025/0166 (2013.01); A61M 2025/09125 (2013.01); A61M 2025/09141 (2013.01); A61M 2025/09166 (2013.01); A61M 2025/09175 (2013.01); A61N 1/327 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of delivering a therapeutic agent to a target tissue, the method comprising:
identifying a target tissue via an imaging modality;
providing a needle having a distal end and a proximal end and a lumen;
inserting the needle into a patient so that its distal end is proximate the target tissue;
inserting a guidewire having a proximal end and a distal end through the lumen of the needle, said guidewire having an anchor member at said distal end;
advancing the guidewire in the lumen so that its distal end is positioned proximate the target tissue;
anchoring said distal end of said guidewire proximate to or in said target tissue using said anchor member;
removing the needle from the patient;
providing a cannula that is removably insertable over said guidewire, said cannula having a proximal end and a distal end and at least first and second lumens therethrough extending between said proximal and distal ends, the cannula having a wall and at least one surface, wherein the cannula is further comprised of two electrodes disposed within the wall of the cannula or on a surface of the cannula at the distal end, wherein the electrodes are disposed on opposed ends of a porous section of the cannula having pores through the cannula wall and wherein said electrodes are coupled to an energy source comprising an electroporator;
removably inserting the proximal end of the guidewire into the first lumens of the cannula and advancing the cannula over the guidewire until the distal end of the cannula is proximate the target tissue;
coupling the second lumen to a source of therapeutic agent at the proximal end of the cannula; and
while the guidewire remains in place within the first lumen of the cannula, delivering the therapeutic agent to the target tissue through the second lumen and porous section of the cannula, wherein the target tissue comprises cells, and the therapeutic agent comprises a therapeutic agent selected from the group consisting of monoclonal antibodies, immunoconjugates, cytokines, oncolytic viruses, vaccines, genetic material, antimicrobial agents, antibiotics, steroids, nonsteroidal anti-inflammatory drugs (NSAIDS), vascular endothelial growth factor (VEGF), growth factor (GF), ethanol and radiosensitizers;
delivering reversible electroporation direct current (DC) electric pulses from the electroporator to cause the therapeutic agent to be delivered into the cells or target tissue; and
uncoupling the second lumen from the source of therapeutic agent and delivering a second treatment to the target tissue through the second lumen.